QualityStocksNewsBreaks – Trxade Group Inc. (NASDAQ: MEDS) Featured in Dougherty & Company LLC Research Report
Trxade Group (NASDAQ: MEDS) was featured in a recent equity research report published by Dougherty & Company LLC. The report reads, “We are initiating coverage of Trxade with a Buy rating and Price Target of $12. MEDS’ primary offering is a web-based platform connecting large suppliers of branded and generic drugs with retail and independent pharmacies. The platform offers full price transparency, comparing the prices and availability across a variety of suppliers. Its latest offering is a direct-to-consumer application equipped with telemedicine visits which includes home delivery of medications. MEDS nearly doubled revenue in 2019 and we model the company…